查詢結果分析
相關文獻
- 嚴重氣喘治療新藥--Benralizumab
- 利用卵白蛋白誘導建立氣喘小鼠模式:評估肺部組織病理學變化和嗜酸性球浸潤相關度
- Airway Hyperreactivity Modulated by Immunotherapy with Denatured Ovalbumin in Ovalbumin-Sensitized Guinea Pigs
- 過敏性氣喘
- 麻杏甘石湯對塵蟍誘發氣喘天竺鼠之影響
- 各年齡層氣喘病人食物過敏率與過敏程度之研究
- The Anti-Inflammatory Effect of a Long-Acting Theophylline (Unidur) in Patients with Bronchial Asthma
- 腎氣丸對塵蟍激發喘天竺鼠呼吸道發炎與免疫之影響
- 如何改善老年人氣喘病的療效
- 小兒氣喘處置之最新發展
頁籤選單縮合
| 題 名 | 嚴重氣喘治療新藥--Benralizumab=A New Medicine in Severe Asthma Treatment--Benralizumab |
|---|---|
| 作 者 | 嚴淑揚; 施美份; | 書刊名 | 藥學雜誌 |
| 卷 期 | 34:2=135 2018.06[民107.06] |
| 頁 次 | 頁77-82 |
| 分類號 | 418.263 |
| 關鍵詞 | 氣喘; 嗜酸性球; IL-5受體alpha單株抗體; Benralizumab; Asthma; Basophils; |
| 語 文 | 中文(Chinese) |
| 中文摘要 | 空氣汙染的結果使得患有氣喘的病人日趨嚴重。典型氣喘治療藥物包括氣管擴 張劑及慢性抗發炎藥物,如β2吸入型作用劑及吸入型類固醇。嚴重頑固氣喘的呼吸道 發現有嗜酸性球的浸潤情形,其症狀控制常需併用多種氣管擴張劑及慢性抗發炎藥 物,部分患者甚至在這些藥物使用至最大劑量時仍無法達到有效症狀控制。嗜酸性 球被活化後會釋出許多導致氣管收縮的媒介物質如介白素 (interleukin (IL))-5,因此許 多相關生物製劑因而陸續被發展出來,幾項大型臨床試驗均顯示 IL-5α 受體單株抗體 Benralizumab 可使用在頑固嚴重氣喘病人之使用。臨床試驗發現使用 Benralizumab 比 起使用安慰劑的病人在使用氣管擴張劑前的「用力呼氣一秒量」(FEV1) 有明顯增加而 氣喘惡化的頻率則顯著減少。由於呼吸道發炎細胞的浸潤往往是頑固型的氣喘及慢性 呼吸道阻塞性疾病的治療阻礙,然引起這些發炎細胞浸潤的路徑可能不盡相同而導致 目前臨床上使用生物製劑並非人人有效,因此未來的治療藥物可能會持續朝不同誘導 發炎細胞浸潤的媒介之單株抗體及小分子藥物等生物製劑開發。 |
| 英文摘要 | Air pollution may lead asthma to become more deteriorate. Typical medications for asthma treatment are those bronchodilators and anti-inflammatory drug, such as inhaled β-agonists and steroids, respectively. Infiltration of basophils in bronchioles is commonly found in refractory severe asthma patients. Several lines of medications, both bronchodilators and anti-inflammatory drug, are required for the symptom control. In addition, maximum dosages are normal needed for optimal control. Activation of basophils can release several cytokines, such as IL-5, which also causes bronchoconstriction. For this reason, several relative drugs have been developed. One of them is Benralizumab, an IL-5 receptor monoclonal antibody, which has been recently developed to be used in refractory severe asthma patients. In several clinical trials, Benralizumab was found to improve forced expiratory volume in one second (FEV1) effectively before using bronchodilator and to reduce severe asthma exacerbations. Although it is known that infiltration of inflammatory cells are the main cause of refractory asthma and chronic obstructive pulmonary disease, the pathways to cause these cells to migrate and infiltrate in the airways are thought to be diverse. For this reason, biological agents may not work at similar effective levels within patients. Asthma medicines, including cytokine monoclonal antibodies and small molecular drugs, may be developed in diverse ways according to their regulatory pathways in the future to overcome those major possible pathways which may cause inflammatory cells to migrate to the airways. |
本系統中英文摘要資訊取自各篇刊載內容。